| Revision as of 18:36, 19 September 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report errors or bugs)← Previous edit |
Latest revision as of 09:18, 22 August 2024 edit undoValenzuela400 (talk | contribs)Extended confirmed users13,305 edits better image |
| (35 intermediate revisions by 30 users not shown) |
| Line 1: |
Line 1: |
|
|
{{short description|Chemical compound}} |
|
{{Wikify|date=July 2011}} |
|
|
|
|
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| verifiedrevid = 447811786 |
|
| verifiedrevid = 451369843 |
|
| IUPAC_name = (2''S'')-3-(4-phenylpiperazin-1-yl)propane-1,2-diol |
|
| IUPAC_name = (2''S'')-3-(4-phenylpiperazin-1-yl)propane-1,2-diol |
|
| image = Levodropropizine.svg |
|
| image = Levodropropizine.svg |
| Line 27: |
Line 27: |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 99291-25-5 |
|
| CAS_number = 99291-25-5 |
|
| ATC_prefix = R05 |
|
| ATC_prefix = R05 |
| Line 32: |
Line 33: |
|
| PubChem = 65859 |
|
| PubChem = 65859 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
| DrugBank = |
|
| DrugBank = DB12472 |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = 59270 |
|
| ChemSpiderID = 59270 |
| Line 39: |
Line 40: |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D08119 |
|
| KEGG = D08119 |
|
|
| ChEBI_Ref = {{ebicite|changed|EBI}} |
|
|
| ChEBI = 82722 |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=13 | H=20 | N=2 | O=2 |
|
| C=13 | H=20 | N=2 | O=2 |
|
| molecular_weight = 236.31 g/mol |
|
|
| smiles = O(CN2CCN(c1ccccc1)CC2)CO |
|
| smiles = O(CN2CCN(c1ccccc1)CC2)CO |
|
| InChI = 1/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1 |
|
|
| InChIKey = PTVWPYVOOKLBCG-ZDUSSCGKBV |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1 |
|
| StdInChI = 1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1 |
| Line 51: |
Line 51: |
|
| StdInChIKey = PTVWPYVOOKLBCG-ZDUSSCGKSA-N |
|
| StdInChIKey = PTVWPYVOOKLBCG-ZDUSSCGKSA-N |
|
}} |
|
}} |
|
'''Levodropropizine''' is a ]. It is the levo isomer of ]. It acts as a peripheral antitussive, with no action in the central nervous system and so does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives. |
|
'''Levodropropizine''' is a ]. It is the ] of ]. It acts as a peripheral antitussive, with no action in the ].<ref>{{cite journal | vauthors = De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A | title = An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome | journal = Cough | volume = 8 | issue = 1 | pages = 1 | date = January 2012 | pmid = 22269875 | pmc = 3274450 | doi = 10.1186/1745-9974-8-1 | doi-access = free }}</ref> It does not cause ] such as ] or ] which can be produced by ] antitussives such as ] and its derivatives. |
|
|
] |
|
|
In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as ] protection for its 2017 registered ] drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine."<ref>{{cite news |last1=Chan-hyuk |first1=Kim |title=Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent|url= https://www.koreabiomed.com/news/articleView.html?idxno=12239|accessdate=July 29, 2024 |publisher=] |date=September 9, 2021}}</ref> In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its ] drug, Levotics CR Tab (levodropropizine).<ref>{{cite news |last1= |first1= |title=Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand|url=https://www.koreabiomed.com/news/articleView.html?idxno=22024 |accessdate=July 29, 2024 |publisher= ]|date=September 9, 2023}}</ref> |
|
|
|
|
|
==External links== |
|
|
* - ] |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
{{Piperazines}} |
|
{{Piperazines}} |
| Line 57: |
Line 65: |
|
|
|
|
|
] |
|
] |
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|
|
{{respiratory-system-drug-stub}} |
|
{{respiratory-system-drug-stub}} |
|
|
|
|
] |
|
|
] |
|